Omnicell (NASDAQ:OMCL) Price Target Raised to $55.00

Omnicell (NASDAQ:OMCL) had its target price boosted by Wells Fargo & Company from $52.00 to $55.00 in a research report report published on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

A number of other equities research analysts have also recently issued reports on OMCL. Benchmark reissued a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a research report on Wednesday, January 7th. Piper Sandler reaffirmed an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. UBS Group set a $60.00 target price on shares of Omnicell and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, Weiss Ratings cut shares of Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, March 2nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of “Moderate Buy” and a consensus price target of $59.00.

Omnicell Stock Performance

NASDAQ OMCL opened at $37.37 on Thursday. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 934.48, a PEG ratio of 1.30 and a beta of 0.85. The stock has a 50-day moving average of $36.83 and a 200 day moving average of $39.19. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). The business had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Sell-side analysts anticipate that Omnicell will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Corey J. Manley sold 7,405 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the transaction, the executive vice president directly owned 96,717 shares in the company, valued at $3,355,112.73. The trade was a 7.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.52% of the stock is owned by company insiders.

Institutional Investors Weigh In On Omnicell

Several hedge funds and other institutional investors have recently made changes to their positions in OMCL. Assenagon Asset Management S.A. grew its holdings in Omnicell by 83.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock valued at $11,698,000 after buying an additional 117,556 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its holdings in shares of Omnicell by 345.9% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock worth $971,000 after acquiring an additional 24,738 shares during the period. Roubaix Capital LLC acquired a new position in shares of Omnicell during the 3rd quarter valued at about $2,326,000. Quantbot Technologies LP acquired a new position in shares of Omnicell during the 3rd quarter valued at about $786,000. Finally, Peregrine Capital Management LLC purchased a new stake in shares of Omnicell in the fourth quarter valued at about $4,804,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.